Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma - Trial NCT01013285
Access comprehensive clinical trial information for NCT01013285 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jonsson Comprehensive Cancer Center and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 70 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jonsson Comprehensive Cancer Center
Timeline & Enrollment
Phase 2
Jun 01, 2006
Aug 01, 2015
Primary Outcome
Overall Survival
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
 ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
 help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
 growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such
 as temozolomide, work in different ways to stop the growth of tumor cells, either by killing
 the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to
 kill tumor cells. Giving bevacizumab together with temozolomide and radiation therapy may
 kill more tumor cells.
 
 PURPOSE: This phase II trial is studying the side effects and how well giving bevacizumab
 together with temozolomide and external beam radiation therapy works when given as first-line
 therapy in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01013285
Non-Device Trial